EXENATIDE PACKAGE INSERT PDF

Serious bleeding, which may be fatal, from drug induced immune mediated thrombocytopenia has been reported with exenatide use [see Warnings and Precautions 5. Pen-sharing poses a risk for transmission of blood-borne pathogens. After initiation of BYETTA, and after dose increases, observe patients carefully for signs and symptoms of pancreatitis including persistent severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by vomiting. Therefore, patients receiving BYETTA and a sulfonylurea may require a lower dose of the sulfonylurea to reduce the risk of hypoglycemia. In patients at increased risk of hypoglycemia consider reducing the dose of insulin [see Adverse Reactions 6. For additional information on glucose-dependent effects see Mechanism of Action

Author:Kizahn Saktilar
Country:Belgium
Language:English (Spanish)
Genre:Personal Growth
Published (Last):10 May 2005
Pages:10
PDF File Size:10.16 Mb
ePub File Size:14.50 Mb
ISBN:260-7-43136-142-1
Downloads:45651
Price:Free* [*Free Regsitration Required]
Uploader:Neshakar



Volabar Exenatide should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Careful monitoring of blood glucose is recommended. Let the autoinjector come to room temperature for approximately 15 minutes before administration. The ijsert is not indicated in infants or neonates. The concurrent use of exenatide with prandial insulin has not been studied.

This product information is intended for US Healthcare Professionals only. Thin or smaller individuals can use a 45 degree angle to avoid intramuscular injection.

In Type 2 diabetes patients with partially intact insulin reserves, octreotide administration may result in decreases in plasma insulin levels and hyperglycemia.

For patients who are to self-administering exenatide, adequate oral as well as written instructions on the use of the injector pen should be supplied before they self-administer a dose. Hemodialysis Exenatide is not recommended for use in patients with end-stage renal disease ESRD on continuous or intermittent hemodialysis. The hyperglycemic effect of diazoxide is expected to be antagonized by certain antidiabetic agents e.

Extended-release exenatide must be injected immediately after suspended in the diluent within the Pen device or the syringe. Do not store the pen with the needle on, as the medication may leak out or air bubbles may form in the cartridge. Constituents in garlic might have some antidiabetic activity, and may increase serum insulin levels and increase glycogen storage in the liver.

PDR Search Moderate Green tea catechins have been shown to decrease serum glucose concentrations in vitro. The two peaks represent the hydration and erosion of the microspheres. Among patients with end-stage renal disease receiving dialysis, the mean exenatide exposure increased by 3. Acetaminophen AUC, Cmax, and Tmax were not significantly changed when acetaminophen was given 1 h before exenatide injection.

Alternatively, administer before the 2 main meals of the day, approximately 6 hours or more apart. Exenatide has not been studied in patients with severe gastrointestinal GI disease, including gastroparesis. In some patients, hypoglycemia can be prolonged. This is followed by a gradual release of exenatide from the microspheres and a second peak around week 6 to 7.

Moderate Cases of an increased INR have been reported with the concomitant use of warfarin and exenatide, sometimes associated with bleeding. Exenatide AUC increased proportionally over the inset dose range of 5 to 10 mcg.

Moderate Niacin nicotinic acid interferes with glucose metabolism and can result in hyperglycemia. Go to Healthcare Professional Site.

Although specific dose recommendations are not available for most agents, the clinician should consider a dose packsge of the insulin secretagogue or insulin when used in combination with exenatide.

Exenatide also slows gastric emptying thereby reducing the rate at which meal-derived glucose appears in the circulation. Clonidine does not appear to impair recovery from hypoglycemia, and has not been found to impair glucose tolerance in diabetic patients. Other oral hypoglycemics may also be considered as possible alternatives in some patients.

Byetta exenatide dose, indications, adverse effects, interactions from Use is not recommended. Patients taking antidiabetic agents and receiving bortezomib treatment may require close monitoring of their blood glucose levels and dosage adjustment of their medication. We encourage you to read the privacy policy of every website you packagr.

Hypoglycemia should be monitored for by the patient and clinician when exenatide treatment is initiated and continued. TOP Related Posts.

THE EXTRAORDINARY CHEMISTRY OF ORDINARY THINGS 4TH EDITION PDF

BYETTA PACKAGE INSERT PDF DOWNLOAD

With each weekly dose, the amount of medicine in your body builds up until it reaches an optimal level after 10 weeks, to help give you consistent control of your blood sugar 7 days a week. Stomach With type 2 diabetes, the stomach moves food along faster than it should, and that sends sugar into the blood faster. Pancreas With type 2 diabetes, too little insulin is produced by the pancreas to keep blood sugar levels normal. Want help for your discussion? Read each statement and choose the answer that best describes you. True I feel uneasy about talking to my doctor about other treatment options.

ARTHUR SCHNITZLER RHAPSODY A DREAM NOVEL PDF

Email your Doctor Discussion Guide

Volabar Exenatide should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Careful monitoring of blood glucose is recommended. Let the autoinjector come to room temperature for approximately 15 minutes before administration. The ijsert is not indicated in infants or neonates. The concurrent use of exenatide with prandial insulin has not been studied.

CHUVA PASMADA PDF

BYETTA PACKAGE INSERT PDF

Got Stop taking BYETTA and packabe your healthcare provider byetta package insert away if you have pain in your stomach area abdomen that is severe, and will not go away, occurs with or without vomiting or is felt going from your abdomen through to your back. All other trademarks are property of their respective owners. Go to Patient Site. Beytta other trademarks are property of their respective owners. Based on animal data, BYETTA may cause fetal harm and should be used during pregnancy only if the potential byetta package insert justifies the potential risk to the fetus. Add BYETTA to insulin glargine as a complementary action to help improve glycemic control Postmarketing reports byetta package insert increased international normalized ratio INR sometimes associated with bleeding with concomitant use of warfarin. Pen-sharing poses a risk for transmission of blood-borne pathogens, even if the needle is changed.

Related Articles